ProCE Banner Activity

Phase III Trial of Pembrolizumab + Chemotherapy vs Chemotherapy Alone in Treatment-Naive Pleural Mesothelioma

Conference Coverage
Slideset

In patients with previously untreated pleural mesothelioma, the addition of pembrolizumab to standard platinum/pemetrexed chemotherapy was associated with statistically significant improvements in OS, PFS, and response rate vs chemotherapy alone.

Released: June 07, 2023

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from AstraZeneca, Daiichi Sankyo, Merck Sharp & Dohme Corp., and Novocure.

AstraZeneca

Daiichi Sankyo

Merck Sharp & Dohme Corp.

Novocure